 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
FFCD-PETACC-8
EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
|
|
| |
Combination Chemotherapy and Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
GERCOR-C04-2
EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2
|
|
| |
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
|
|
|
|
Phase III
|
|
|
|
CALGB-C80405
C80405, SWOG-C80405, NCT00265850
|
|
| |
A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis
|
|
|
|
Phase III
|
|
|
|
JCOG0504
C000000307, NCT00280475
|
|
| |
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer
|
|
|
|
Phase III
|
|
|
|
tasmc-05-na-05160-ctil
NCT00295035
|
|
| |
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
|
|
|
|
Phase III
|
|
|
|
EFC5505
SR57746A, NCT00305188
|
|
| |
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
|
|
|
|
Phase III
|
|
|
|
CTRU-PICCOLO-MO-05-7289
EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870
|
|
| |
Partnership for Healthy Seniors
|
|
|
|
Phase III
|
|
|
|
IRB00000063
NCT00379743
|
|
| |
Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
TMDU-BRI-CC-05-01
NCT00392899
|
|
| |
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
|
|
|
|
Phase III
|
|
|
|
MCSGO-CCTG-0501
NCT00385970
|
|
